-
公开(公告)号:US20090054341A1
公开(公告)日:2009-02-26
申请号:US12247141
申请日:2008-10-07
CPC分类号: A61K38/26 , A61K31/00 , A61K38/2278 , Y10S514/866
摘要: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译: 公开了增加尿流量的方法,包括施用有效量的GLP-1,毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症,例如肾衰竭,充血性心力衰竭,肾病综合征,肝硬化,肺水肿和高血压。 本发明还涉及诱导肌力反应的方法,包括施用有效量的GLP-1,毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号:US20130281394A1
公开(公告)日:2013-10-24
申请号:US13880720
申请日:2011-10-18
IPC分类号: C07C309/46 , A61K31/167 , C07C233/75 , C07D307/85 , A61K31/343 , C07D317/68 , A61K31/36 , C07C237/08 , A61K31/198 , C07D209/20 , A61K31/405 , C07C69/533 , A61K31/216 , C07C69/28 , A61K31/704 , A61K31/7016 , A61K31/4709 , A61K31/201 , C07C235/64
CPC分类号: C07C309/46 , A61K9/2054 , A61K9/2086 , A61K9/2846 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/192 , A61K31/197 , A61K31/198 , A61K31/201 , A61K31/216 , A61K31/343 , A61K31/36 , A61K31/405 , A61K31/4709 , A61K31/7016 , A61K31/704 , A61K38/05 , C07C69/28 , C07C69/533 , C07C233/75 , C07C235/64 , C07C237/08 , C07D209/20 , C07D307/85 , C07D317/68
摘要: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
摘要翻译: 本文提供了通过施用包含化学感应受体配体的组合物来治疗与化学感觉受体相关的病症的方法,包括糖尿病,肥胖症和其它代谢疾病,病症或病症。 本文还提供了用于本发明方法的化学感应受体配体组合物及其制备方法。
-
公开(公告)号:US20110195904A1
公开(公告)日:2011-08-11
申请号:US13080051
申请日:2011-04-05
CPC分类号: G09G3/3233 , G09G2300/0452 , G09G2300/0465 , G09G2300/0804 , G09G2300/0819 , G09G2300/0852 , G09G2300/0861 , G09G2310/0235 , G09G2310/0251 , G09G2320/043 , H01L27/3211 , H01L27/3244
摘要: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译: 公开了增加尿流量的方法,包括施用有效量的GLP-1,毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症,例如肾衰竭,充血性心力衰竭,肾病综合征,肝硬化,肺水肿和高血压。 本发明还涉及诱导肌力反应的方法,包括施用有效量的GLP-1,毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号:US20150064223A1
公开(公告)日:2015-03-05
申请号:US14370449
申请日:2012-07-11
IPC分类号: A61K31/155 , A61K31/55 , A61K9/20 , A61K31/357 , A61K31/485 , A61K45/06 , A61K31/137
CPC分类号: A61K31/155 , A61K9/2018 , A61K9/2054 , A61K9/209 , A61K9/2846 , A61K31/137 , A61K31/357 , A61K31/485 , A61K31/55 , A61K31/7048 , A61K45/06 , A61K2300/00
摘要: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
摘要翻译: 本文提供了通过施用包含双胍或相关杂环化合物(例如二甲双胍)的组合来治疗某些病症(包括糖尿病,肥胖症和其它代谢疾病,病症或病症)的方法。 本文还提供双胍类或相关杂环化合物组合物及其制备用于本发明方法的方法。 本文还提供包含二甲双胍及其盐及其使用方法的组合物。
-
公开(公告)号:US20130303466A1
公开(公告)日:2013-11-14
申请号:US13880718
申请日:2011-10-18
IPC分类号: A61K38/06 , A61K31/4402 , A61K31/44 , A61K31/341 , A61K31/357 , A61K31/365 , A61K31/704 , A61K31/661 , A61K31/121 , A61K31/4015 , A61K31/198 , A61K31/23
CPC分类号: A61K38/06 , A61K31/121 , A61K31/198 , A61K31/23 , A61K31/231 , A61K31/341 , A61K31/357 , A61K31/365 , A61K31/401 , A61K31/4015 , A61K31/44 , A61K31/4402 , A61K31/661 , A61K31/683 , A61K31/704 , A61K45/06 , C07K5/0215 , C07K5/0808 , C07K5/0815 , C07K5/0819
摘要: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
-
公开(公告)号:US20130281387A1
公开(公告)日:2013-10-24
申请号:US13880719
申请日:2011-10-18
IPC分类号: A61K31/706 , A61K45/06 , A61K31/194 , A61K31/165 , A61K31/255 , A61K31/661 , A61K31/662 , A61K31/44 , A61K31/5377 , A61K31/4439 , A61K31/4545 , A61K31/426 , A61K31/42 , A61K31/341 , A61K31/704 , A61K31/20 , A61K31/7008
CPC分类号: A61K31/706 , A61K31/164 , A61K31/165 , A61K31/185 , A61K31/194 , A61K31/195 , A61K31/198 , A61K31/20 , A61K31/23 , A61K31/231 , A61K31/255 , A61K31/275 , A61K31/341 , A61K31/415 , A61K31/42 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4439 , A61K31/4545 , A61K31/5377 , A61K31/661 , A61K31/662 , A61K31/7008 , A61K31/7034 , A61K31/704 , A61K45/06
摘要: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
-
公开(公告)号:US20130338095A1
公开(公告)日:2013-12-19
申请号:US13880717
申请日:2011-10-18
IPC分类号: C07H19/20 , C07D213/56 , C07D285/16 , C07F7/08 , C07D241/24 , C07D495/04 , C07D317/68 , C07D493/04
CPC分类号: C07H19/20 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/216 , A61K31/277 , A61K31/34 , A61K31/36 , A61K31/381 , A61K31/40 , A61K31/4025 , A61K31/4184 , A61K31/4192 , A61K31/42 , A61K31/423 , A61K31/44 , A61K31/4402 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/444 , A61K31/4965 , A61K31/497 , A61K31/505 , A61K31/517 , A61K31/519 , A61K31/549 , A61K31/7068 , A61K31/7076 , A61K45/06 , C07C233/11 , C07C233/51 , C07C233/65 , C07C235/34 , C07C235/46 , C07C235/48 , C07C235/78 , C07C255/57 , C07C275/30 , C07C275/34 , C07C323/62 , C07C2601/14 , C07C2602/10 , C07D213/40 , C07D213/56 , C07D241/24 , C07D285/16 , C07D317/68 , C07D333/24 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D493/04 , C07D495/04 , C07F7/0812 , C07F9/65586 , C07H7/02
摘要: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
-
公开(公告)号:US20120177730A1
公开(公告)日:2012-07-12
申请号:US13345135
申请日:2012-01-06
申请人: Alain D. BARON , Martin R. BROWN , Christopher R.G. JONES , Nigel R.A. BEELEY , Mark S. FINEMAN
发明人: Alain D. BARON , Martin R. BROWN , Christopher R.G. JONES , Nigel R.A. BEELEY , Mark S. FINEMAN
CPC分类号: A61K31/155 , A61K9/0053 , A61K9/2054 , A61K9/209 , A61K9/2846 , A61K9/4808 , A61K31/19 , A61K31/198 , A61K31/7016 , A61K31/704 , A61K45/06
摘要: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
摘要翻译: 本文提供了通过施用包含化学感应受体配体如苦味受体配体的组合物来治疗与化学感觉受体相关的病症(包括糖尿病,肥胖症和其它代谢疾病,病症或病症)的方法。 本文还提供了化学感应受体配体组合物,包括苦味受体配体组合物及其制备用于本发明方法的方法。 本文还提供包含二甲双胍及其盐及其使用方法的组合物。
-
公开(公告)号:US08759291B2
公开(公告)日:2014-06-24
申请号:US13080051
申请日:2011-04-05
IPC分类号: A61K38/22 , C07K14/575
CPC分类号: G09G3/3233 , G09G2300/0452 , G09G2300/0465 , G09G2300/0804 , G09G2300/0819 , G09G2300/0852 , G09G2300/0861 , G09G2310/0235 , G09G2310/0251 , G09G2320/043 , H01L27/3211 , H01L27/3244
摘要: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
摘要翻译: 公开了增加尿流量的方法,包括施用有效量的GLP-1,毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 还公开了增加尿钠排泄量和降低尿钾浓度的方法。 该方法可用于治疗与毒性高血容量相关的病症或病症,例如肾衰竭,充血性心力衰竭,肾病综合征,肝硬化,肺水肿和高血压。 本发明还涉及诱导肌力反应的方法,包括施用有效量的GLP-1,毒蜥外泌肽或毒蜥外泌肽或GLP-1激动剂。 这些方法可用于治疗可通过增加心脏收缩力如充血性心力衰竭而减轻的病症或障碍。 还公开了用于本发明方法的药物组合物。
-
公开(公告)号:US20140030332A1
公开(公告)日:2014-01-30
申请号:US13978514
申请日:2012-01-06
申请人: Alain D. Baron , Martin R. Brown , Christopher R.G. Jones , Nigel R.A. Beeley , Mark S. Fineman
发明人: Alain D. Baron , Martin R. Brown , Christopher R.G. Jones , Nigel R.A. Beeley , Mark S. Fineman
IPC分类号: A61K31/155 , A61K31/704 , A61K9/00 , A61K31/198 , A61K45/06 , A61K31/19 , A61K31/7016
CPC分类号: A61K31/155 , A61K9/0053 , A61K9/2054 , A61K9/209 , A61K9/2846 , A61K9/4808 , A61K31/19 , A61K31/198 , A61K31/7016 , A61K31/704 , A61K45/06
摘要: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
摘要翻译: 本文提供了通过施用包含化学感应受体配体如苦味受体配体的组合物来治疗与化学感觉受体相关的病症(包括糖尿病,肥胖症和其它代谢疾病,病症或病症)的方法。 本文还提供了化学感应受体配体组合物,包括苦味受体配体组合物及其制备用于本发明方法的方法。 本文还提供包含二甲双胍及其盐及其使用方法的组合物。
-
-
-
-
-
-
-
-
-